High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

BACKGROUND: Imatinib is the standard of care for newly diagnosed chronic-phase chronic myeloid leukemia. The largest randomized clinical trial of imatinib was the multinational IRIS trial in which 1106 patients were randomized to receive either imatinib 400 mg/day or a standard regimen of interferon...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Guilhot, François, Druker, Brian, Larson, Richard A., Gathmann, Insa, So, Charlene, Waltzman, Roger, O’Brien, Stephen G.
Format: Artigo
Jezik:Inglês
Izdano: Ferrata Storti Foundation 2009
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2791923/
https://ncbi.nlm.nih.gov/pubmed/19648168
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2009.010629
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki